Ventripoint Provides Corporate Update on Development of Next-Generation Products
Toronto, Ontario, August 13, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to present an update on its progress to provide better tools for cardiac analysis to cardiologists to improve diagnosis and treatment of heart disease.
Software upgrades to speed analysis and improve reproducibility between exams
The Company previously announced (see NR, March 19, 2018) a collaboration with Ryerson University to use its Artificial Intelligence (AI) expertise to develop a software engine to automatically detect all four chambers of the heart in echocardiographic views. If successful, this will reduce time spent on analysis and training, and allow sequential exams conducted by different users to be compared with confidence. Even today, the comparison of sequential exams is difficult to interpret due to operator variability in image acquisition, making analysis, and therefore disease progression hard to quantify. Automated analysis will ensure comparability between sequential studies.
The University researchers have completed an initial prototype of the AI engine. This software can be used to detect the end systolic and end diastolic frames in cardiac video clips in a number of different views. In initial testing with images provided by the Company, results were impressive with an up to 90% accuracy rate in identifying cardiac ultrasound views. More images are being provided to the Ryerson team to further the development of their deep-learning algorithm to enable automatic, real-time cardiac-feature detection using AI on ultrasound imaging.
It is important to accurately assess the heart using all ultrasound imaging machines and the faster the better. The Ryerson project is aimed at offering a real-time automated analysis package for cardiac analysis. An accurate reproducible result is critical in assessing disease progression. We are encouraged with the progress of our collaboration.
Annual General Meeting
The Company is holding its Annual General Meeting today at its corporate offices in Toronto at 2:00 pm EST. The prototype of the new VMS+ 3.0 will be available for viewing. More details are included in the circular, which has been mailed to shareholders of record.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint’s expectations, should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.